Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Formulation and Delivery Comparison# Afamelanotide (Scenesse)# The pharmaceutical formulation uses a controlled-release bioresorbable implant: Melanotan-1 (Research Peptide)# The research peptide version is sold as lyophilized powder: Mechanism of Action# Both afamelanotide and melanotan-1 share the same mechanism: MC1R binding : The peptide binds to melanocortin-1 receptors (MC1R) on melanocytes with high affinity and longer duration than native alpha-MSH Adenylyl cyclase activation : MC1R activation stimulates adenylyl cyclase, increasing intracellular cAMP PKA/CREB pathway : cAMP activates protein kinase A, which phosphorylates CREB transcription factor MITF induction : CREB activates the MITF gene, the master regulator of melanocyte function Eumelanin synthesis : MITF upregulates tyrosinase and other enzymes in the eumelanin biosynthetic pathway Photoprotection : Increased eumelanin provides UV absorption and free radical scavenging The key distinction from alpha-MSH is the substitutions at positions 4 (norleucine replaces methionine) and 7 (D-phenylalanine replaces L-phenylalanine), which increase metabolic stability from minutes to hours
doi: 10.1016/j.jdiacomp.2014.12.006 27 LamersDFamullaSWronkowitzNHartwigSLehrSOuwensDMet al
ALCAR was either administered orally (4 g/day for 90 days) in four trials or intravenously (4 g/day for three days) in one trial
Patients taking GLP-1 medications should be aware of warning signs that warrant consultation with healthcare services
Subgroup analyses further reveal that the protective effect of SGLT2 inhibitors varies by age, sex, and disease onset period, suggesting that multiple factors influence the observed outcomes
US$ 22.47
US$ 22.82
US$ 28.61
US$ 24.33
US$ 25.13
US$ 23.16
US$ 20.45
US$ 27.82
US$ 21.31
